Clinical benefits of continuous leukocyte filtration during cardiopulmonary bypass in patients undergoing valvular repair or replacement

Perfusion

Volumn 20, Issue 1, 2005, Pages 21-29

  Sutton, Steven W ^a,b   Patel, A N ^a   Chase, V A ^a   Schmidt, L A ^a   Hunley, E K ^a   Yancey, L W ^a   Hebeler, R F ^a   Cheung, E H ^a   Henry III, A C ^a   Meyers, T P ^a   Wood, R E ^a  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^b Baylor University Medical Center ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; AORTA CLAMPING; AORTA VALVE REPLACEMENT; ARTICLE; CARDIOPULMONARY BYPASS; CELL SEPARATION; COHORT ANALYSIS; CONTROLLED STUDY; EXTRACORPOREAL CIRCULATION; FEMALE; FILTRATION; HEART VALVE REPLACEMENT; HUMAN; LENGTH OF STAY; LYMPHOCYTE ACTIVATION; MAJOR CLINICAL STUDY; MALE; MITRAL VALVE REPLACEMENT; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; SURGICAL TECHNIQUE;

CARDIOPULMONARY BYPASS; COHORT STUDIES; FEMALE; HEART VALVE PROSTHESIS IMPLANTATION; HEART VALVES; HUMANS; LENGTH OF STAY; LEUKOCYTE REDUCTION PROCEDURES; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; VENTILATOR WEANING;

EID: 20044377590     PISSN: 02676591     EISSN: None     Source Type: Journal    
DOI: 10.1191/0267659105pf781oa     Document Type: Article

References (69)

1. Edmunds LH Jr, Clark RE, Cohn LH et al. Guidelines for reporting morbidity and mortality after cardiac valvular operations. Ann Thorac Surg 1988; 46: 257-59.
2. Kirklin JK. Prospects for understanding and eliminating the deleterious effects of cardiopulmonary bypass. Ann Thorac Surg 1991; 51: 529-31.
3. Maggart M, Stewart S. The mechanisms and management of non-cardiogenic pulmonary edema following cardiopulmonary bypass. Ann Thorac Surg 1987; 43: 231-36.
4. Hashimoto K, Miyamoto H, Suzuki K et al. Evidence of organ damage after cardiopulmonary bypass. The role of elastase and vasoactive mediators. J Thorac Cardiovasc Surg 1992; 104: 666-73.
5. Wan S, Le Clerc JL, Vincent JL. Inflammatory response to cardiopulmonary bypass. Mechanisms involved and possible therapeutic strategies. Chest 1997; 112: 676-92.
6. Asimakopoulos G, Taylor KM. Effects of cardiopulmonary bypass on leukocyte and endothelial adhesion molecules. Ann Thorac Surg 1998; 66: 2135-44.
7. Westaby S. Complement and the damaging effects of cardiopulmonary bypass. Thorax 1983; 38: 321-25.
8. Jansen NJ, van Oeveren W, Gu YJ et al. Endotoxin release and tumor necrosis factor formation during cardiopulmonary bypass. Ann Thorac Surg 1992; 54: 744-47.
9. Chenoweth DE, Cooper SW, Hugli TE et al. Complement activation during cardiopulmonary bypass: evidence for generation of C3a and C5a anaphylotoxins. New Engl J Med 1981; 304: 497-503.
10. Schiel L, Burns S, Nogawa A et al. X Coating™: a new biopassive polymer coating. Can Perfusion Canadienne 2001; 11 8-17.
11. Conti VR. Pulmonary injury after cardiopulmonary bypass. Chest 2001; 119: 2-4.
12. Bukley GB. Reactive oxygen metabolites and reperfusion injury: aberrant triggering of reticuloendothelial function. Lancet 1994; 344: 934-36.
13. Fransen E, Maessen J, Dentener M et al. Systemic inflammation present in patients undergoing CABG without extracorporeal circulation. Chest 1998; 113: 1290-95.
14. Tárnock A, Hambsch J, Emmrich F et al. Complement activation, cytokines and adhesion molecules in children undergoing cardiac surgery with or without cardiopulmonary bypass. Pediatr Cardiol 1999; 20: 113-25.
15. Wachtfogel YT, Kucich U, Greenplate J et al. Human neutrophil degranulation during extracorporeal circulation. Blood 1987; 69: 324-30.
16. Gillinov AM, Bator JM, Zehr KJ et al. Neutrophil adhesion molecule expression during cardiopulmonary bypass with bubble and membrane oxygenators. Ann Thorac Surg 1993; 56: 847-53.
17. Chello M, Mastroroberto P, Romano R et al. Complement and neutrophil activation during cardiopulmonary bypass: a randomized comparison of hypothermic and normothermic circulation. Eur J Cardiothorac Surg 1997; 11: 162-68.
18. Kotani N, Hashimoto H, Sessler DI et al. Neutrophil number and interleukin-8 and elastase concentrations in bronchoalveolar lavage correlate with decreased arterial oxygenation after cardiopulmonary bypass. Anesth Analg 2000; 90: 1046-51.
19. Le Deist F, Menasché P, Kucharski C et al. Hypothermia during cardiopulmonary bypass delays but does not prevent neutrophil-endothelial cell adhesion. Circulation 1995; 92: 354-58.
20. Paugam C, Chollet-Martin S, Dehoux M et al. Neutrophil expression of CD11b/CD18 and IL-8 secretion during normothermic cardiopulmonary bypass. J Cardiothorac Vasc Anesth 1997; 11: 575-79.
21. Chello M, Mastroroberto P, Quirino A et al. Inhibition of neutrophil apoptosis after coronary bypass operation with cardiopulmonary bypass. Ann Thorac Surg 2002; 73: 123-30.
22. Quiroga MM, Miyagishima R, Haendschen LC et al. The effect of body temperature on leukocyte kinetics during cardiopulmonary bypass. J Thorac Cardiovasc Surg 1985; 90: 91-96.
23. Dernek S, Tunerir B, Sevin B et al. The effects of methylprednisolone and pulmonary neutrophil sequestration during cardiopulmonary bypass. Cardiovasc Surg 1999; 7: 414-18.
24. Hill G, Pohorecki R, Alonso A et al. Aprotinin reduces interleukin-8 production and lung neutrophil accumulation after cardiopulmonary bypass. Anesth Analg 1996; 83: 696-700.
25. Hill GE, Alonso A, Thiele GM, Robbins RA. Glucocorticoids blunt neutrophil CD11b surface glycoprotein upregulation during cardiopulmonary bypass in humans. Anesth Analg 1994; 79: 23-27.
26. Soeparwata R, Hartman AR, Frerichmann U et al. Aprotinin diminishes inflammatory processes. I J Cardiol 1996; 53: S55-63.
27. Chello M, Mastroroberto P, Patti G et al. Simvastatin attenuates leucocyte-endothelial interactions after coronary revascularization with cardiopulmonary bypass. Heart 2003; 89 538-43.
28. Finn A, Morgan BP, Rebuck N et al. Effects of inhibition of complement activation using recombinant soluble complement receptor 1 on neutrophil CD11B/CD18 and L-selectin expression and release of interleukin-8 and elastase in simulated cardiopulmonary. J Thorac Cardiovasc Surg 1996; 111: 451-59.
29. Loop FD, Higgins TL, Panda R et al. Myocardial protection during cardiac operations. Decreased morbidity and lower cost with blood cardioplegia and coronary sinus perfusion. J Thorac Cardiovasc Surg 1992; 104: 608-18.
30. Matheis G, Scholz M, Gerber J et al. Leukocyte filtration in the early reperfusion phase on cardiopulmonary bypass reduces myocardial injury. Perfusion 2001; 16: 43-49.
31. Gibbon JH Jr. Application of a mechanical heart and lung apparatus to cardiac surgery. Minn Med 1954; 37: 171-85.
32. Kirklin JK, Westaby S, Blackstone EH et al. Complement and the damaging effects of cardiopulmonary bypass. J Cardiovasc Surg 1983; 86: 845-57.
33. Gott JP, Cooper WA, Schmidt Jr. FE et al. Modifying risk for extracorporeal circulation: trial of four anti-inflammatory strategies. Ann Thorac Surg 1998; 66: 747-53.
34. Shapira N, Zabatino SM, Ahmed S et al. Determinants of pulmonary function in patients undergoing coronary bypass operations. Ann Thorac Surg 1990; 50: 268-73.
35. Ozawa T, Yoshihara K, Koyama N et al. Clinical efficacy of heparin-bonded bypass circuits related to cytokine responses in children. Ann Thorac Surg 2000; 69: 584-90.
36. Grossi EA, Kallenbach K, Chau S et al. Impact of heparin bonding on pediatric cardiopulmonary bypass: a prospective randomized study. Ann Thorac Surg 2000; 70: 191-96.
37. Di Salvo C, Loucca LL, Pattichis K et al. Does activated neutrophil depletion on bypass by leukocyte filtration reduce myocardial damage. J Cardiovasc Surg 1996; 37: 93-100.
38. Hurst T, Johnson D, Cujec B et al. Depletion of activated neutrophils by a filter during cardiac valve surgery. Can J Anesth 1997; 44: 131-39.
39. Smit JJJ, de Vries AJ, Gu YJ, van Oeveren W. Filtration of activated granulocytes during cardiopulmonary bypass surgery: a morphologic and immunologic study to characterize the trapped leukocytes. J Lab Clin Med 2000; 135: 238-46.
40. Johnson D, Thomson D, Mycyk T et al. Depletion of neutrophils by filter during aortocoronary bypass surgery transiently improves postoperative cardiorespiratory status. Chest 1995; 107 1253-59.
41. Bando K, Pillai R, Cameron DE et al. Leukocyte depletion ameliorates free radical mediated lung injury after cardiopulmonary bypass. J Thorac Cardiovasc Surg 1990; 99: 873-77.
42. Chen YF, Tsai WC, Lin CC et al. Leukocyte depletion attenuates expression of neutrophil adhesion molecules during cardiopulmonary bypass in human beings. J Thorac Cardiovasc Surg 2002; 123: 218-24.
43. Wilson IC, Gardner TJ, DiNatale JM et al. Temporary leukocyte depletion reduces ventricular dysfunction during prolonged postischemic reperfusion. J Thorac Cardiovasc Surg 1993; 106: 805-10.
44. Gu YJ, de Vries AJ, Boonstra PW, van Oeveren W. Leukocyte depletion results in improved lung function and reduced inflammatory response after cardiac surgery. J Thorac Cardiovasc Surg 1996; 112: 494-500.
45. Coleman SM, Demastrice L. Leukocyte depletion reduces postoperative oxygen requirements (letter). Ann Thorac Surg 1994; 58: 1567-68.
46. Sawa Y, Taniguchi K, Kadoba K et al. Leukocyte depletion attenuates reperfusion injury in patients with left ventricular hypertrophy. Circulation 1996; 93: 1640-46.
47. Allen BS, Rahman S, Ilbawi MN et al. Detrimental effects of cardiopulmonary bypass in cyanotic infants: preventing the reoxygenation injury. Ann Thorac Surg 1997; 64: 1381-87.
48. Gott JP. Leukodepletion and aprotinin improve clinical outcome after extracorporeal circulation. Perfusion 2001; 16: 5-9.
49. Stefanou DC, Gourlay T, Asimakopoulos G, Taylor KM. Leucodepletion during cardiopulmonary bypass reduces blood transfusion and crystalloid requirements. Perfusion 2001; 16: 51-58.
50. Taylor GJ, Mikell FL, Moses HW et al. Determinants of hospital charges for coronary artery bypass surgery: the economic consequences of postoperative complications. Am J Cardiol 1990; 65: 309-13.
51. Palanzo DA, Manley NJ. Cost effectiveness of using a leuko-depleting arterial line filter. Proc Am Acad Cardiovasc Perfusion 1994; 15: 124-27.
52. Journois D, Israel-Biet D, Pouard P et al. High-volume, zero-balanced hemofiltration to reduce delayed inflammatory response to cardiopulmonary bypass in children. Anesthesiology 1996; 86: 965-76.
53. Ming ZD, Wei W, Hong C, Wei Z, Xiang DW. Balanced ultrafiltration, modified ultrafiltration, and balanced ultrafiltration with modified ultrafiltration in pediatric cardiopulmonary bypass. J Extra Corpor Technol 2001; 33: 223-26.
54. Abdel-Barr TMF, Refaat LAA. The influence of aprotinin, hemofiltration, or both on pro-inflammatory cytokines in pediatric patients undergoing surgical correction of congenital acyanotic heart diseases. Egypt J Anesth 2002; 18: 5-13.
55. Darling E, Searles B, Nasrallah F et al. High-volume, zero balanced ultrafiltration improves pulmonary function in a model of post-pump syndrome. J Extra Corpor Technol 2002; 34: 254-59.
56. Naik SK, Knight A, Elliott M. A prospective randomized study of a modified technique of ultrafiltration during pediatric open-heart surgery. Circulation 1991; 84: 422-31.
57. Watanabe T, Sakai Y, Mayumi T et al. Effect of ultrafiltration during cardiopulmonary bypass for pediatric cardiac surgery. Artif Organs 1998; 22: 1525-94.
58. Gadaleta D, Fahey AL, Verma M et al. Neutrophil leukotriene generation increases after cardiopulmonary bypass. J Thorac Cardiovasc Surg 1994; 108: 642-47.
59. Utoh J, Yamamoto T, Miyauchi Y. Is an increase in neutrophil leukotriene-generating capacity a specific phenomenon for cardiopulmonary bypass? J Thorac Cardiovasc Surg 1995; 110: 276-77.
60. Lust RM, Bode AP, Yang L et al. In-line leukocyte filtration during bypass. Clinical results from a randomized prospective trial. Am Soc Artif Intern Organs 1996; 42: M819-22.
61. Sahlman A, Ahonen J, Salo JA, Rämö OJ. No impact of a leukocyte depleting arterial line filter on patient recovery after cardiopulmonary bypass. Acta Anaesthesiol Scand 2001; 45: 558-63.
62. Fabbri A, Manfredi J, Piccin C et al. Systemic leukocyte filtration during cardiopulmonary bypass. Perfusion 2001; 16: 11-18.
63. Simon A, Scholz M, Aybek T et al. Leukocyte filtration fails to prevent neutrophil-mediated pathogenicity during cardiac surgery in high risk patients. German Society for Cardiovascular Engineering. 2002. Thorac Cardiovasc Surg 2003 THEMA: Permanent Poster Exhibition.
64. Mihaljevic T, Tönz M, von Segesser LK et al. The influence of leukocyte filtration during cardiopulmonary bypass on postoperative lung function: a clinical study. J Thorac Cardiovasc Surg 1995; 109: 1138-45.
65. Thurlow PJ, Doolan L, Sharp R et al. Laboratory studies of the effect of Pall extracorporeal leucocyte filters LG6 and AV6 on patients undergoing coronary bypass grafts. Perfusion 1996; 11 29-37.
66. Sheppard SV. Mechanisms and technical aspects of leukocyte depletion. In Sheppard SV ed. Leukocyte depletion in cardiac surgery and cardiology, Volume 1. 2002: 16-32. Karger, Basel, Switzerland.
67. Efstathiou A, Vlachveis M, Tsonis G et al. Does leukodepletion during elective cardiac surgery really influence the overall clinical outcome? J Cardiovasc Surg 2003; 44: 197-204.
68. Matheis G, Scholz M, Simon A et al. Timing of leukocyte filtration during cardiopulmonary bypass. Perfusion 2001; 16: 31-37.
69. Smit JJ, de Vries AJ, Gu YJ, van Oeveren W. Efficiency and safety of leukocyte filtration during cardiopulmonary bypass for cardiac surgery. Transfus Sci 1999; 20: 151-65.